[BDSI] BioDelivery Sciences International, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 1.75 Change: 0.05 (2.94%)
Ext. hours: Change: 0 (0%)

chart BDSI

Refresh chart

Strongest Trends Summary For BDSI

BDSI is in the long-term up 118% in 1 year and up 99% in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: BioDelivery Sciences International, Inc., a specialty pharmaceutical company, develops and commercializes therapeutics in the areas of pain management and oncology supportive care. The company provides its products based on its patented BioErodible MucoAdhesive (BEMA) drug delivery technology, which consists of a small, bi-layered erodible polymer film for application to the buccal mucosa. Its products include ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in patients with cancer; and BEMA Buprenorphine that is in Phase III trial for the treatment of chronic pain in a mixed opioid naïve and opioid experienced population. The company is also involved in the development of BUNAVAIL for the maintenance treatment of opioid dependence; and Clonidine Topical Gel for the treatment of painful diabetic neuropathy. It has a licensing and development agreement with Endo Pharmaceuticals, Inc. to develop and commercialize BEMA Buprenorphine; and license agreement with Arcion Therapeutics.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-0.35 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -5.98% Sales Growth - Q/Q412.53% P/E-6.57
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-70.05% ROE-115.89% ROI-109.33%
Current Ratio2.42 Quick Ratio2.34 Long Term Debt/Equity0.05 Debt Ratio0.59
Gross Margin82.95% Operating Margin-150.93% Net Profit Margin-184.52% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-1.86 M Cash From Investing Activities-140 K Cash From Operating Activities-5 M Gross Profit11.93 M
Net Profit-8.19 M Operating Profit-7.8 M Total Assets82.47 M Total Current Assets71.74 M
Total Current Liabilities29.59 M Total Debt10.26 M Total Liabilities32.62 M Total Revenue13.05 M
Technical Data
High 52 week5.3 Low 52 week1.7 Last close4.57 Last change-0.44%
RSI36.36 Average true range0.19 Beta0.69 Volume448.88 K
Simple moving average 20 days-5.36% Simple moving average 50 days-6.96% Simple moving average 200 days16.74%
Performance Data
Performance Week-7.86% Performance Month-2.35% Performance Quart-1.3% Performance Half26.24%
Performance Year134.36% Performance Year-to-date23.51% Volatility daily1.98% Volatility weekly4.43%
Volatility monthly9.07% Volatility yearly31.42% Relative Volume117.27% Average Volume1.09 M
New High New Low


2019-06-24 08:00:00 | BioDelivery Sciences Expands Upon Report from Pain Management Task Force

2019-06-21 10:37:02 | The Zacks Analyst Blog Highlights: Middlesex Water, Atlantic Power, NexPoint Residential Trust, Illumina and BioDelivery Sciences International

2019-06-20 09:18:01 | 5 Top Rate-Sensitive Stocks to Buy Amid Fed's Rate Cut Hints

2019-06-20 08:00:00 | BioDelivery Sciences Named to the Russell 3000® Index

2019-06-19 20:43:15 | Here’s What Hedge Funds Think About BioDelivery Sciences International, Inc. BDSI

2019-06-05 09:30:01 | Why Is BioDelivery BDSI Down 12.3% Since Last Earnings Report?

2019-05-31 08:33:48 | Triangle company uses new financial strength to lock down favorable loan

2019-05-29 16:10:00 | BioDelivery Sciences Announces Upcoming Investor Conference Presentations

2019-05-28 16:10:00 | BioDelivery Sciences Strengthens Financial Position with Debt Refinancing

2019-05-28 07:46:56 | Can You Imagine How Chuffed BioDelivery Sciences International's NASDAQ:BDSI Shareholders Feel About Its 108% Share Price Gain?

2019-05-23 09:19:01 | The Zacks Analyst Blog Highlights: Cambrex, Innoviva, Celgene, BioDelivery Sciences International and Unity Biotechnology

2019-05-22 07:21:11 | 5 Biotech Stocks to Gain From Trade Deal Rally on the Horizon

2019-05-21 09:00:01 | All You Need to Know About BioDelivery BDSI Rating Upgrade to Buy

2019-05-07 09:40:01 | BioDelivery BDSI Stock Up on Q1 Earnings and Sales Beat

2019-05-07 07:58:41 | Edited Transcript of BDSI earnings conference call or presentation 6-May-19 8:30pm GMT

2019-05-06 22:03:33 | BioDelivery Sciences International, Inc. BDSI Q1 2019 Earnings Call Transcript

2019-05-06 18:45:10 | BioDelivery Sciences International BDSI Reports Q1 Loss, Tops Revenue Estimates

2019-05-06 17:40:42 | BioDelivery: 1Q Earnings Snapshot

2019-05-06 16:05:00 | BioDelivery Sciences Reports Strong First Quarter 2019 Results and Raises BELBUCA® Full-Year Expectations

2019-05-02 10:32:02 | Will BioDelivery Sciences International BDSI Report Negative Q1 Earnings? What You Should Know

2019-05-02 10:11:02 | What's in Store for BioDelivery BDSI This Earnings Season?

2019-04-25 16:30:00 | BioDelivery Sciences to Report First Quarter 2019 Financial Results

2019-04-17 09:00:01 | What Makes BioDelivery BDSI a New Buy Stock

2019-04-13 09:30:01 | BioDelivery BDSI Up 7.8% Since Last Earnings Report: Can It Continue?

2019-04-11 10:45:25 | BDSI expects $50 million in latest public offering

2019-04-11 09:34:01 | BioDelivery BDSI Buys US Rights to Pain Drug for $30M

2019-04-11 09:29:00 | BioDelivery Sciences International, Inc. Announces Pricing of Public Offering of Common Stock

2019-04-11 07:48:23 | The Daily Biotech Pulse: NASH Cheer For Intercept, Gilead Layoffs, BioDelivery Licenses Constipation Drug

2019-04-11 07:25:27 | BDSI announces public offering after paying $30M for drug rights

2019-04-10 16:07:52 | BioDelivery Sciences International, Inc. Announces Proposed Underwritten Public Offering of Common Stock

2019-04-10 16:06:08 | BioDelivery Sciences Acquires U.S. Commercial Rights to Symproic®

2019-03-27 17:45:09 | BioDelivery Sciences International BDSI Dips More Than Broader Markets: What You Should Know

2019-03-22 18:24:00 | Lifshitz & Miller LLP Announces Investigation of Alta Mesa Resources, Inc., American Renal Associates LLC, Belden, Inc., BioDelivery Sciences, Inc., Blue Valley Bank Corp., Bridgepoint Education, Inc., and Care.com, Inc.

2019-03-21 17:45:09 | BioDelivery Sciences International BDSI Gains But Lags Market: What You Should Know

2019-03-19 14:26:06 | Catalyst CPRX Reports Wider Q4 Loss, Focuses on Firdapse

2019-03-18 18:44:10 | Bristol-Myers & Pfizer Release Phase IV Data on Eliquis

2019-03-15 10:23:02 | BioDelivery BDSI Q4 Earnings In Line, Sales Beat, Stock Up

2019-03-14 23:51:23 | Edited Transcript of BDSI earnings conference call or presentation 14-Mar-19 8:30pm GMT

2019-03-14 20:20:00 | Biodelivery Sciences International Inc BDSI Q4 2018 Earnings Conference Call Transcript

2019-03-14 19:45:29 | BioDelivery: 4Q Earnings Snapshot

2019-03-14 16:05:00 | BioDelivery Sciences Reports Strong 2018 Results and 2019 Expectations

2019-03-14 14:30:00 | BioDelivery Sciences International, Inc. to Host Earnings Call

2019-03-13 12:50:04 | Aerie AERI Receives FDA Nod for Rocklatan to Treat Glaucoma

2019-03-12 10:58:13 | BioDelivery Sciences Investigated by Block & Leviton LLP For Violations of Federal Securities Laws

2019-03-12 09:59:01 | Alnylam Files Application for Hypertension Candidate in UK

2019-03-11 14:38:35 | What Kind Of Shareholder Appears On The BioDelivery Sciences International, Inc.’s NASDAQ:BDSI Shareholder Register?

2019-03-11 10:35:02 | AMAG's Stock Down as Pregnancy Drug Fails in PROLONG Study

2019-03-11 10:00:02 | What Makes BioDelivery Sciences International BDSI a Strong Momentum Stock: Buy Now?

2019-03-11 09:56:01 | Will the Decade-Old Bull Market Momentum Last? 5 Picks

2019-03-05 16:36:09 | What's in Store for BioSpecifics BSTC This Earnings Season?